These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35222509)

  • 21. Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein.
    Kinami T; Amioka K; Kawaoka T; Uchikawa S; Yamasaki S; Kosaka M; Johira Y; Yano S; Naruto K; Ando Y; Yamaoka K; Fujii Y; Fujino H; Nakahara T; Ono A; Murakami E; Okamoto W; Yamauchi M; Miki D; Tsuge M; Imamura M; Aikata H; Oka S
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility.
    Yu Q; Wang Y; Ungchusri E; Patel M; Kumari D; Van Ha T; Pillai A; Liao CY; Ahmed O
    J Interv Med; 2023 Nov; 6(4):187-193. PubMed ID: 38312131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future.
    Li L; Liu HT; Teng YX; Deng ZJ; Zhang GL; Su JY; Ma L; Zhong JH
    Expert Opin Investig Drugs; 2022 Nov; 31(11):1151-1167. PubMed ID: 36437752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy.
    Oura K; Morishita A; Manabe T; Takuma K; Nakahara M; Tadokoro T; Fujita K; Mimura S; Tani J; Ono M; Ogawa C; Moriya A; Senoo T; Tsutsui A; Nagano T; Takaguchi K; Himoto T; Masaki T
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
    Liu SV; Camidge DR; Gettinger SN; Giaccone G; Heist RS; Hodi FS; Ready NE; Zhang W; Wallin J; Funke R; Waterkamp D; Foster P; Iizuka K; Powderly J
    Eur J Cancer; 2018 Sep; 101():114-122. PubMed ID: 30053670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Bangaru S; Marrero JA; Singal AG
    Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic therapy for hepatocellular carcinoma: current status and future perspectives.
    Furuse J; Ueno M; Ikeda M
    Jpn J Clin Oncol; 2021 Aug; 51(9):1363-1371. PubMed ID: 34258616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
    Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
    J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).
    Haber PK; Puigvehí M; Castet F; Lourdusamy V; Montal R; Tabrizian P; Buckstein M; Kim E; Villanueva A; Schwartz M; Llovet JM
    Gastroenterology; 2021 Sep; 161(3):879-898. PubMed ID: 34126063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic therapies for hepatocellular carcinoma: the present and the future.
    Celsa C; Giuffrida P; Stornello C; Grova M; Spatola F; Rizzo GEM; Busacca A; Cannella R; Battaglia S; Cammà C; Cabibbo G
    Recenti Prog Med; 2021 Feb; 112(2):110-116. PubMed ID: 33624623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities.
    Laface C; Fedele P; Maselli FM; Ambrogio F; Foti C; Molinari P; Ammendola M; Lioce M; Ranieri G
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
    Liu W; Quan B; Lu S; Tang B; Li M; Chen R; Ren Z; Yin X
    Front Oncol; 2021; 11():771045. PubMed ID: 35004289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study.
    Yoo C; Kim JH; Ryu MH; Park SR; Lee D; Kim KM; Shim JH; Lim YS; Lee HC; Lee J; Tai D; Chan SL; Ryoo BY
    Liver Cancer; 2021 Apr; 10(2):107-114. PubMed ID: 33977087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current treatment options for hepatocellular carcinoma.
    Eugen K
    Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors.
    Piñero F; Silva M; Iavarone M
    World J Gastroenterol; 2020 Apr; 26(16):1888-1900. PubMed ID: 32390700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.
    Shimose S; Iwamoto H; Tanaka M; Niizeki T; Kajiwara M; Itano S; Moriyama E; Shirono T; Noda Y; Kamachi N; Nakano M; Kuromatsu R; Koga H; Kawaguchi T
    Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of different systemic combination therapies on advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Li P; Hu M; Liu M; Ren X; Liu D; Liu J; Yin J; Tan X; Cao G
    Front Oncol; 2023; 13():1197782. PubMed ID: 37817769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.